Skip to main content
Article thumbnail
Location of Repository

The context and potential of epigenetics in oncology

By J Lopez, M Percharde, H M Coley, A Webb and T Crook

Abstract

Cancer has long been known to be a disease caused by alterations in the genetic blueprint of cells. In the past decade it has become evident that epigenetic processes have a function, at least equally important, in neoplasia. Epigenetics describes the mechanisms that result in heritable alterations in gene expression profiles without an accompanying change in DNA sequence. Genetics and epigenetics intricately interact in the pathogenesis of cancer (Esteller, 2007). In this review, we paint a broad picture of current understanding of epigenetic changes in cancer cells and reflect on the immense clinical potential of emerging knowledge of epigenetics in the diagnosis, prognostic assessment, treatment, and screening of cancer

Topics: Clinical Studies
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2653733
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). 62: 2370–2377 Berger SL
    2. (2004). Invest 111: 887–895
    3. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997–1003 Context and potential of epigenetics in oncology J Lopez et al British Journal of Cancer (2009) 100(4), 571–577 &
    4. (2007). Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
    5. (2005). Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.